RESEARCH

ZUPREVO® has been proven in countless trials and studies.

Zuprevo-Speed-of-Action-TSB

ZUPREVO Proven speed of action in dairy calf ranches in California, feedyards in Nebraska and starter yards in Alabama

Download PDF

Zuprevo-HistophilusSomni

Histophilosis: The compelling case for using ZUPREVO in treatment of BRD caused by Histophilus somni

Download PDF

Zuprevo-Canada-TSB

Canadian commercial feedlot study comparing ZUPREVO to Draxxin® and Micotil® when used on arrival in calves at high risk of developing BRD

Download PDF

Zuprevo-10-Day-Challenge-Study-TSB

Determination of the amount of pulmonary lesions when cattle are challenged with Mannheimia haemolytica 10 days after administration of either tildipirosin (ZUPREVO) or tulathromycin (Draxxin®)

Download PDF

Zuprevo-tildipirosin-Antibiotic-BRD-Risk-Factor-Check-List

ZUPREVO (tildipirosin) Antibiotic BRD Risk Factor Check List

Download PDF

Comparison-of-Zuprevo-tildipirosin-and-Draxxin-tulathromycin-in-the-Control-of-BRD-in-Calf-Ranch-Cattle

Comparison of ZUPREVO (tildipirosin) and Draxxin (tulathromycin) in the Control of BRD in Calf Ranch Cattle

Download PDF

Technical-Bulletin-5-day-Histophillus-Challenge

Technical Bulletin: 5 day Histophilus Challenge

Download PDF

Technical-Bulletin-Zuprevo-vs.-Nuflor-Draxxin-and-Bio-Mycin-2016

Technical Bulletin: ZUPREVO vs. Nuflor, Draxxin and Bio-Mycin_2016

Download PDF

No items to show.

Loading…

Important Safety Information

FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOID ACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NO ADDITIONAL PROTECTION SYSTEM. IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT OR LABEL TO THE PHYSICIAN.

RESIDUE WARNING: Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of this drug product in these cattle may cause milk residue. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

The effects of ZUPREVO® 18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond slaughter withdrawal period. This may result in trim loss of edible tissue at slaughter.

DO NOT USE ZUPREVO® 18% IN SWINE. FATAL ADVERSE EVENTS HAVE BEEN REPORTED FOLLOWING THE USE OF TILDIPIROSIN IN SWINE. NOT FOR USE IN CHICKENS OR TURKEYS.

Sign up to receive cattle health management insights, industry news and more sent straight to your inbox.